FNY Investment Advisers LLC Makes New Investment in uniQure (NASDAQ:QURE)

FNY Investment Advisers LLC purchased a new stake in shares of uniQure (NASDAQ:QUREFree Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 5,004 shares of the biotechnology company’s stock, valued at approximately $88,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Franklin Resources Inc. purchased a new stake in uniQure in the third quarter valued at approximately $7,360,000. Geode Capital Management LLC boosted its holdings in shares of uniQure by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock worth $2,509,000 after purchasing an additional 6,362 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new position in shares of uniQure during the 3rd quarter valued at about $283,000. Quarry LP purchased a new position in shares of uniQure during the 3rd quarter valued at about $58,000. Finally, RTW Investments LP bought a new stake in uniQure in the 3rd quarter worth approximately $49,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Price Performance

QURE opened at $13.99 on Thursday. The stock’s 50 day moving average price is $11.83 and its 200-day moving average price is $8.24. uniQure has a 52-week low of $3.73 and a 52-week high of $19.18. The stock has a market capitalization of $681.91 million, a PE ratio of -2.82 and a beta of 0.41. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51.

uniQure (NASDAQ:QUREGet Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($1.12) by $0.21. The business had revenue of $2.29 million during the quarter, compared to analyst estimates of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. On average, equities research analysts predict that uniQure will post -3.82 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have commented on QURE shares. Wells Fargo & Company upgraded shares of uniQure from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 10th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of uniQure in a research note on Tuesday, December 10th. Royal Bank of Canada boosted their target price on uniQure from $14.00 to $20.00 and gave the company an “outperform” rating in a research note on Wednesday, December 11th. Mizuho lifted their price target on uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a research note on Thursday, December 19th. Finally, Cantor Fitzgerald boosted their price objective on uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a research report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $33.88.

Check Out Our Latest Stock Analysis on QURE

Insiders Place Their Bets

In other news, CEO Matthew C. Kapusta sold 3,418 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the completion of the transaction, the chief executive officer now owns 597,915 shares in the company, valued at $4,562,091.45. This trade represents a 0.57 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.74% of the stock is currently owned by company insiders.

About uniQure

(Free Report)

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

Featured Stories

Institutional Ownership by Quarter for uniQure (NASDAQ:QURE)

Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.